JP3188586B2 - Hot patch - Google Patents
Hot patchInfo
- Publication number
- JP3188586B2 JP3188586B2 JP10200094A JP10200094A JP3188586B2 JP 3188586 B2 JP3188586 B2 JP 3188586B2 JP 10200094 A JP10200094 A JP 10200094A JP 10200094 A JP10200094 A JP 10200094A JP 3188586 B2 JP3188586 B2 JP 3188586B2
- Authority
- JP
- Japan
- Prior art keywords
- protective layer
- reinforcing portion
- hot patch
- sensitive adhesive
- adhesive layer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000011241 protective layer Substances 0.000 claims description 101
- 230000003014 reinforcing effect Effects 0.000 claims description 60
- 239000010410 layer Substances 0.000 claims description 42
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims description 41
- -1 polypropylene Polymers 0.000 claims description 19
- 229920003002 synthetic resin Polymers 0.000 claims description 11
- 239000000057 synthetic resin Substances 0.000 claims description 11
- 239000004698 Polyethylene Substances 0.000 claims description 6
- 239000004743 Polypropylene Substances 0.000 claims description 6
- 229920000573 polyethylene Polymers 0.000 claims description 6
- 229920001155 polypropylene Polymers 0.000 claims description 6
- 229920000728 polyester Polymers 0.000 claims description 5
- 229920000915 polyvinyl chloride Polymers 0.000 claims description 5
- 239000004800 polyvinyl chloride Substances 0.000 claims description 5
- 239000004793 Polystyrene Substances 0.000 claims description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 4
- 229910052782 aluminium Inorganic materials 0.000 claims description 4
- 239000011888 foil Substances 0.000 claims description 4
- 238000010030 laminating Methods 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 229920002223 polystyrene Polymers 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 description 27
- 239000003795 chemical substances by application Substances 0.000 description 22
- 239000012790 adhesive layer Substances 0.000 description 21
- 239000010408 film Substances 0.000 description 14
- 239000000126 substance Substances 0.000 description 12
- 239000000853 adhesive Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 230000001070 adhesive effect Effects 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 229920000642 polymer Polymers 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 8
- 229920005989 resin Polymers 0.000 description 8
- 239000011347 resin Substances 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- 229920001400 block copolymer Polymers 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 6
- 239000003208 petroleum Substances 0.000 description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000178 monomer Substances 0.000 description 5
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 229920001971 elastomer Polymers 0.000 description 4
- NPERTKSDHFSDLC-UHFFFAOYSA-N ethenol;prop-2-enoic acid Chemical compound OC=C.OC(=O)C=C NPERTKSDHFSDLC-UHFFFAOYSA-N 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000011505 plaster Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000005060 rubber Substances 0.000 description 4
- 210000004243 sweat Anatomy 0.000 description 4
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 3
- 125000002723 alicyclic group Chemical group 0.000 description 3
- 238000013329 compounding Methods 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 229960001047 methyl salicylate Drugs 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000002787 reinforcement Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- 241000723346 Cinnamomum camphora Species 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- RBBWCVQDXDFISW-UHFFFAOYSA-N Feprazone Chemical compound O=C1C(CC=C(C)C)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 RBBWCVQDXDFISW-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 229930008380 camphor Natural products 0.000 description 2
- 229960000846 camphor Drugs 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 2
- 229940106681 chloroacetic acid Drugs 0.000 description 2
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 239000005038 ethylene vinyl acetate Substances 0.000 description 2
- 238000004299 exfoliation Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 229960000489 feprazone Drugs 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229960002389 glycol salicylate Drugs 0.000 description 2
- 230000020169 heat generation Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229960001067 hydrocortisone acetate Drugs 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical compound [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 235000019477 peppermint oil Nutrition 0.000 description 2
- 229960002508 pindolol Drugs 0.000 description 2
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 229920001083 polybutene Polymers 0.000 description 2
- 239000005033 polyvinylidene chloride Substances 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 238000007665 sagging Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229920002994 synthetic fiber Polymers 0.000 description 2
- 239000012209 synthetic fiber Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 1
- CEMAWMOMDPGJMB-UHFFFAOYSA-N (+-)-Oxprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1OCC=C CEMAWMOMDPGJMB-UHFFFAOYSA-N 0.000 description 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- UHSXRTHJCJGEKG-UQKRIMTDSA-N (1s)-1-[(3,4,5-trimethoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinolin-2-ium-6,7-diol;chloride Chemical compound Cl.COC1=C(OC)C(OC)=CC(C[C@H]2C3=CC(O)=C(O)C=C3CCN2)=C1 UHSXRTHJCJGEKG-UQKRIMTDSA-N 0.000 description 1
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- QHZUABXEBRGBLP-LKWYKXIFSA-N (6aR,9R,10aR)-N-[(2R,4R,9aS,9bR)-4-benzyl-9b-hydroxy-3,5-dioxo-2-propan-2-yl-3a,4,7,8,9,9a-hexahydrofuro[3,2-g]indolizin-2-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide (6aR,9R,10aR)-N-[(2R,4R,9aS,9bR)-9b-hydroxy-3,5-dioxo-2,4-di(propan-2-yl)-3a,4,7,8,9,9a-hexahydrofuro[3,2-g]indolizin-2-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide (6aR,10aR)-N-[(2S,4S,9bS)-9b-hydroxy-4-(2-methylpropyl)-3,5-dioxo-2-propan-2-yl-3a,4,7,8,9,9a-hexahydrofuro[3,2-g]indolizin-2-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.CS(O)(=O)=O.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)C4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)C)C(C)C)=C3C2=CNC3=C1.C1=CC([C@H]2CC(CN(C)[C@@H]2C2)C(=O)N[C@@]3(C(=O)C4[C@@H](C(N5CCCC5[C@@]4(O)O3)=O)CC(C)C)C(C)C)=C3C2=CNC3=C1.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(C21)=O)(NC(=O)[C@H]1CN(C)[C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C(C)C)C1=CC=CC=C1 QHZUABXEBRGBLP-LKWYKXIFSA-N 0.000 description 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- OBRNDARFFFHCGE-PERKLWIXSA-N (S,S)-formoterol fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 OBRNDARFFFHCGE-PERKLWIXSA-N 0.000 description 1
- PMGQWSIVQFOFOQ-BDUVBVHRSA-N (e)-but-2-enedioic acid;(2r)-2-[2-[1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine Chemical compound OC(=O)\C=C\C(O)=O.CN1CCC[C@@H]1CCOC(C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 PMGQWSIVQFOFOQ-BDUVBVHRSA-N 0.000 description 1
- BFUXUGOZJVHVMR-UHFFFAOYSA-N 1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound N1CNS(=O)(=O)C2=CC(S(=O)(=O)N)=CC=C21 BFUXUGOZJVHVMR-UHFFFAOYSA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- YGTUPRIZNBMOFV-UHFFFAOYSA-N 2-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)C1=CC=C(O)C=C1 YGTUPRIZNBMOFV-UHFFFAOYSA-N 0.000 description 1
- WYUYEJNGHIOFOC-VVTVMFAVSA-N 2-[(z)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridine;hydrochloride Chemical compound Cl.C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C\CN1CCCC1 WYUYEJNGHIOFOC-VVTVMFAVSA-N 0.000 description 1
- JIEKMACRVQTPRC-UHFFFAOYSA-N 2-[4-(4-chlorophenyl)-2-phenyl-5-thiazolyl]acetic acid Chemical compound OC(=O)CC=1SC(C=2C=CC=CC=2)=NC=1C1=CC=C(Cl)C=C1 JIEKMACRVQTPRC-UHFFFAOYSA-N 0.000 description 1
- VSKJLJHPAFKHBX-UHFFFAOYSA-N 2-methylbuta-1,3-diene;styrene Chemical compound CC(=C)C=C.C=CC1=CC=CC=C1.C=CC1=CC=CC=C1 VSKJLJHPAFKHBX-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- AWRLZJJDHWCYKN-UHFFFAOYSA-N 5-bromo-2-ethoxy-3-nitropyridine Chemical compound CCOC1=NC=C(Br)C=C1[N+]([O-])=O AWRLZJJDHWCYKN-UHFFFAOYSA-N 0.000 description 1
- BKYKPTRYDKTTJY-UHFFFAOYSA-N 6-chloro-3-(cyclopentylmethyl)-1,1-dioxo-3,4-dihydro-2H-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1CCCC1 BKYKPTRYDKTTJY-UHFFFAOYSA-N 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- SWECWXGUJQLXJF-BTJKTKAUSA-N Dimetindene maleate Chemical compound OC(=O)\C=C/C(O)=O.CN(C)CCC=1CC2=CC=CC=C2C=1C(C)C1=CC=CC=N1 SWECWXGUJQLXJF-BTJKTKAUSA-N 0.000 description 1
- ZVXBAHLOGZCFTP-UHFFFAOYSA-N Efloxate Chemical compound C=1C(OCC(=O)OCC)=CC=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 ZVXBAHLOGZCFTP-UHFFFAOYSA-N 0.000 description 1
- URJQOOISAKEBKW-UHFFFAOYSA-N Emorfazone Chemical compound C1=NN(C)C(=O)C(OCC)=C1N1CCOCC1 URJQOOISAKEBKW-UHFFFAOYSA-N 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- BALXUFOVQVENIU-GNAZCLTHSA-N Ephedrine hydrochloride Chemical compound Cl.CN[C@@H](C)[C@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-GNAZCLTHSA-N 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- VXLCNTLWWUDBSO-UHFFFAOYSA-N Ethiazide Chemical compound ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)NC(CC)NC2=C1 VXLCNTLWWUDBSO-UHFFFAOYSA-N 0.000 description 1
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
- WMFSSTNVXWNLKI-UHFFFAOYSA-N Flutazolam Chemical compound O1CCN2CC(=O)N(CCO)C3=CC=C(Cl)C=C3C21C1=CC=CC=C1F WMFSSTNVXWNLKI-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- MUQNGPZZQDCDFT-JNQJZLCISA-N Halcinonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@@H]2O MUQNGPZZQDCDFT-JNQJZLCISA-N 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- 239000004831 Hot glue Substances 0.000 description 1
- ACEWLPOYLGNNHV-UHFFFAOYSA-N Ibuprofen piconol Chemical compound C1=CC(CC(C)C)=CC=C1C(C)C(=O)OCC1=CC=CC=N1 ACEWLPOYLGNNHV-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- CYLWJCABXYDINA-UHFFFAOYSA-N Polythiazide Polymers ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CSCC(F)(F)F)NC2=C1 CYLWJCABXYDINA-UHFFFAOYSA-N 0.000 description 1
- TVQZAMVBTVNYLA-UHFFFAOYSA-N Pranoprofen Chemical compound C1=CC=C2CC3=CC(C(C(O)=O)C)=CC=C3OC2=N1 TVQZAMVBTVNYLA-UHFFFAOYSA-N 0.000 description 1
- MWQCHHACWWAQLJ-UHFFFAOYSA-N Prazepam Chemical compound O=C1CN=C(C=2C=CC=CC=2)C2=CC(Cl)=CC=C2N1CC1CC1 MWQCHHACWWAQLJ-UHFFFAOYSA-N 0.000 description 1
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- PPTYJKAXVCCBDU-UHFFFAOYSA-N Rohypnol Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1F PPTYJKAXVCCBDU-UHFFFAOYSA-N 0.000 description 1
- 208000007613 Shoulder Pain Diseases 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 229920013623 Solprene Polymers 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 229920002978 Vinylon Polymers 0.000 description 1
- FPVRUILUEYSIMD-RPRRAYFGSA-N [(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(OC(C)=O)[C@@]1(C)C[C@@H]2O FPVRUILUEYSIMD-RPRRAYFGSA-N 0.000 description 1
- RMCARYIDWQXUND-UHFFFAOYSA-N [CH2-]C(=O)C.C(C)(=O)O Chemical compound [CH2-]C(=O)C.C(C)(=O)O RMCARYIDWQXUND-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229960004538 alprazolam Drugs 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229960002213 alprenolol Drugs 0.000 description 1
- PAZJSJFMUHDSTF-UHFFFAOYSA-N alprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1CC=C PAZJSJFMUHDSTF-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229960003099 amcinonide Drugs 0.000 description 1
- ILKJAFIWWBXGDU-MOGDOJJUSA-N amcinonide Chemical compound O([C@@]1([C@H](O2)C[C@@H]3[C@@]1(C[C@H](O)[C@]1(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]13)C)C(=O)COC(=O)C)C12CCCC1 ILKJAFIWWBXGDU-MOGDOJJUSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- YEJAJYAHJQIWNU-UHFFFAOYSA-N azelastine hydrochloride Chemical compound Cl.C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 YEJAJYAHJQIWNU-UHFFFAOYSA-N 0.000 description 1
- 229960004335 azelastine hydrochloride Drugs 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 229960003515 bendroflumethiazide Drugs 0.000 description 1
- HDWIHXWEUNVBIY-UHFFFAOYSA-N bendroflumethiazidum Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1=CC=CC=C1 HDWIHXWEUNVBIY-UHFFFAOYSA-N 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- 229950004580 benzyl nicotinate Drugs 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229960001102 betamethasone dipropionate Drugs 0.000 description 1
- CIWBQSYVNNPZIQ-XYWKZLDCSA-N betamethasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-XYWKZLDCSA-N 0.000 description 1
- PLCQGRYPOISRTQ-LWCNAHDDSA-L betamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-LWCNAHDDSA-L 0.000 description 1
- 229960005354 betamethasone sodium phosphate Drugs 0.000 description 1
- SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 description 1
- 229960004311 betamethasone valerate Drugs 0.000 description 1
- QRZAKQDHEVVFRX-UHFFFAOYSA-N biphenyl-4-ylacetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=CC=C1 QRZAKQDHEVVFRX-UHFFFAOYSA-N 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 229960000330 bupranolol Drugs 0.000 description 1
- HQIRNZOQPUAHHV-UHFFFAOYSA-N bupranolol Chemical compound CC1=CC=C(Cl)C(OCC(O)CNC(C)(C)C)=C1 HQIRNZOQPUAHHV-UHFFFAOYSA-N 0.000 description 1
- 229920005549 butyl rubber Polymers 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 229940007061 capsicum extract Drugs 0.000 description 1
- 239000001943 capsicum frutescens fruit extract Substances 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- GVNWHCVWDRNXAZ-BTJKTKAUSA-N carbinoxamine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 GVNWHCVWDRNXAZ-BTJKTKAUSA-N 0.000 description 1
- 229960000456 carbinoxamine maleate Drugs 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 229960001222 carteolol Drugs 0.000 description 1
- LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 description 1
- 239000003576 central nervous system agent Substances 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- DERZBLKQOCDDDZ-JLHYYAGUSA-N cinnarizine Chemical compound C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C\C=C\C1=CC=CC=C1 DERZBLKQOCDDDZ-JLHYYAGUSA-N 0.000 description 1
- 229960000876 cinnarizine Drugs 0.000 description 1
- 229960002689 clemastine fumarate Drugs 0.000 description 1
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 1
- 229960004703 clobetasol propionate Drugs 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 229960003932 cloxazolam Drugs 0.000 description 1
- ZIXNZOBDFKSQTC-UHFFFAOYSA-N cloxazolam Chemical compound C12=CC(Cl)=CC=C2NC(=O)CN2CCOC21C1=CC=CC=C1Cl ZIXNZOBDFKSQTC-UHFFFAOYSA-N 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 125000006841 cyclic skeleton Chemical group 0.000 description 1
- 229960003206 cyclopenthiazide Drugs 0.000 description 1
- 229960003596 cyproheptadine hydrochloride Drugs 0.000 description 1
- ZPMVNZLARAEGHB-UHFFFAOYSA-N cyproheptadine hydrochloride (anhydrous) Chemical compound Cl.C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 ZPMVNZLARAEGHB-UHFFFAOYSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003657 dexamethasone acetate Drugs 0.000 description 1
- 229960004833 dexamethasone phosphate Drugs 0.000 description 1
- VQODGRNSFPNSQE-CXSFZGCWSA-N dexamethasone phosphate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP(O)(O)=O)(O)[C@@]1(C)C[C@@H]2O VQODGRNSFPNSQE-CXSFZGCWSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- KBEZZLAAKIIPFK-NJAFHUGGSA-N dimemorfan Chemical compound C1C2=CC=C(C)C=C2[C@@]23CCN(C)[C@@H]1[C@H]2CCCC3 KBEZZLAAKIIPFK-NJAFHUGGSA-N 0.000 description 1
- 229960001056 dimemorfan Drugs 0.000 description 1
- 229940099401 dimethindene maleate Drugs 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 229960003859 efloxate Drugs 0.000 description 1
- 208000024764 elbow pain Diseases 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 229950010243 emorfazone Drugs 0.000 description 1
- OYFJQPXVCSSHAI-QFPUQLAESA-N enalapril maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 OYFJQPXVCSSHAI-QFPUQLAESA-N 0.000 description 1
- 229960000309 enalapril maleate Drugs 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 229960002534 ephedrine hydrochloride Drugs 0.000 description 1
- 229960002336 estazolam Drugs 0.000 description 1
- CDCHDCWJMGXXRH-UHFFFAOYSA-N estazolam Chemical compound C=1C(Cl)=CC=C(N2C=NN=C2CN=2)C=1C=2C1=CC=CC=C1 CDCHDCWJMGXXRH-UHFFFAOYSA-N 0.000 description 1
- 229950004659 estradiol enanthate Drugs 0.000 description 1
- RFWTZQAOOLFXAY-BZDYCCQFSA-N estradiol enanthate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCC)[C@@]1(C)CC2 RFWTZQAOOLFXAY-BZDYCCQFSA-N 0.000 description 1
- 229950007164 ethiazide Drugs 0.000 description 1
- UQXKXGWGFRWILX-UHFFFAOYSA-N ethylene glycol dinitrate Chemical compound O=N(=O)OCCON(=O)=O UQXKXGWGFRWILX-UHFFFAOYSA-N 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 229960000192 felbinac Drugs 0.000 description 1
- 229960001037 fenoterol hydrobromide Drugs 0.000 description 1
- 229960002679 fentiazac Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229960004930 fludiazepam Drugs 0.000 description 1
- ROYOYTLGDLIGBX-UHFFFAOYSA-N fludiazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F ROYOYTLGDLIGBX-UHFFFAOYSA-N 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- 229960002200 flunitrazepam Drugs 0.000 description 1
- 229960001048 fluorometholone Drugs 0.000 description 1
- FAOZLTXFLGPHNG-KNAQIMQKSA-N fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 description 1
- 229960002690 fluphenazine Drugs 0.000 description 1
- 229960003528 flurazepam Drugs 0.000 description 1
- SAADBVWGJQAEFS-UHFFFAOYSA-N flurazepam Chemical compound N=1CC(=O)N(CCN(CC)CC)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F SAADBVWGJQAEFS-UHFFFAOYSA-N 0.000 description 1
- 229950009354 flutazolam Drugs 0.000 description 1
- 229960000193 formoterol fumarate Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 229960002383 halcinonide Drugs 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229950000177 hibenzate Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229950005954 ibuprofen piconol Drugs 0.000 description 1
- 229950008838 indenolol Drugs 0.000 description 1
- MPGBPFMOOXKQRX-UHFFFAOYSA-N indenolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1C=CC2 MPGBPFMOOXKQRX-UHFFFAOYSA-N 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000011256 inorganic filler Substances 0.000 description 1
- 229910003475 inorganic filler Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- YNQQEYBLVYAWNX-WLHGVMLRSA-N ketotifen fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 YNQQEYBLVYAWNX-WLHGVMLRSA-N 0.000 description 1
- 229960003630 ketotifen fumarate Drugs 0.000 description 1
- 208000024765 knee pain Diseases 0.000 description 1
- 229960004400 levonorgestrel Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- 229960002373 loxoprofen Drugs 0.000 description 1
- YMBXTVYHTMGZDW-UHFFFAOYSA-N loxoprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1CC1C(=O)CCC1 YMBXTVYHTMGZDW-UHFFFAOYSA-N 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- LZULAZTXJLWELL-UHFFFAOYSA-N methyl hex-5-ynoate Chemical compound COC(=O)CCCC#C LZULAZTXJLWELL-UHFFFAOYSA-N 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- IYJMSDVSVHDVGT-PEQKVOOWSA-N metildigoxin Chemical compound O1[C@H](C)[C@@H](OC)[C@@H](O)C[C@@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O IYJMSDVSVHDVGT-PEQKVOOWSA-N 0.000 description 1
- 229960003746 metildigoxin Drugs 0.000 description 1
- 229950000412 mexazolam Drugs 0.000 description 1
- ANUCDXCTICZJRH-UHFFFAOYSA-N mexazolam Chemical compound C=1C=C(Cl)C=C2C=1NC(=O)CN1C(C)COC21C1=CC=CC=C1Cl ANUCDXCTICZJRH-UHFFFAOYSA-N 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 229960002497 nicorandil Drugs 0.000 description 1
- LBHIOVVIQHSOQN-UHFFFAOYSA-N nicorandil Chemical compound [O-][N+](=O)OCCNC(=O)C1=CC=CN=C1 LBHIOVVIQHSOQN-UHFFFAOYSA-N 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229950001981 nimetazepam Drugs 0.000 description 1
- GWUSZQUVEVMBPI-UHFFFAOYSA-N nimetazepam Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1 GWUSZQUVEVMBPI-UHFFFAOYSA-N 0.000 description 1
- 229960001454 nitrazepam Drugs 0.000 description 1
- KJONHKAYOJNZEC-UHFFFAOYSA-N nitrazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1 KJONHKAYOJNZEC-UHFFFAOYSA-N 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- 229960004535 oxazepam Drugs 0.000 description 1
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
- 229950006124 oxazolam Drugs 0.000 description 1
- VCCZBYPHZRWKFY-XIKOKIGWSA-N oxazolam Chemical compound C1([C@]23C4=CC(Cl)=CC=C4NC(=O)CN2C[C@H](O3)C)=CC=CC=C1 VCCZBYPHZRWKFY-XIKOKIGWSA-N 0.000 description 1
- 229960004570 oxprenolol Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
- 229960005301 pentazocine Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920000346 polystyrene-polyisoprene block-polystyrene Polymers 0.000 description 1
- 229960005483 polythiazide Drugs 0.000 description 1
- 229920000046 polythiazide Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229960003101 pranoprofen Drugs 0.000 description 1
- 229960004856 prazepam Drugs 0.000 description 1
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
- 229960001289 prazosin Drugs 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- BOFKYYWJAOZDPB-FZNHGJLXSA-N prednival Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O BOFKYYWJAOZDPB-FZNHGJLXSA-N 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960001309 procaine hydrochloride Drugs 0.000 description 1
- 229960002789 procaterol hydrochloride Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 1
- 229960003111 prochlorperazine Drugs 0.000 description 1
- XXPDBLUZJRXNNZ-UHFFFAOYSA-N promethazine hydrochloride Chemical compound Cl.C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 XXPDBLUZJRXNNZ-UHFFFAOYSA-N 0.000 description 1
- 229960002244 promethazine hydrochloride Drugs 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 239000002964 rayon Substances 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 229920003051 synthetic elastomer Polymers 0.000 description 1
- 239000005061 synthetic rubber Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960003676 tenidap Drugs 0.000 description 1
- LXIKEPCNDFVJKC-QXMHVHEDSA-N tenidap Chemical compound C12=CC(Cl)=CC=C2N(C(=O)N)C(=O)\C1=C(/O)C1=CC=CS1 LXIKEPCNDFVJKC-QXMHVHEDSA-N 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 229960002784 thioridazine Drugs 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- NZHGWWWHIYHZNX-CSKARUKUSA-N tranilast Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-CSKARUKUSA-N 0.000 description 1
- 229960005342 tranilast Drugs 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 229960003386 triazolam Drugs 0.000 description 1
- JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229960001593 triprolidine hydrochloride Drugs 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 229960004747 ubidecarenone Drugs 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000010455 vermiculite Substances 0.000 description 1
- 229910052902 vermiculite Inorganic materials 0.000 description 1
- 235000019354 vermiculite Nutrition 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Thermotherapy And Cooling Therapy Devices (AREA)
Description
【0001】[0001]
【産業上の利用分野】本発明は医薬又は医療用,家庭
用,レジャー用に供される使い捨てカイロや温熱シップ
剤,温熱プラスター等の温熱貼付剤に関するものであ
る。更に詳しくは、発熱部剤の一面に沿って略全面又は
部分的若しくは枠状等に展着された粘着剤層全面にわた
り密着された保護層の側部や角部に形成された補強部を
有し、補強部の形成部を指先でめくるだけで高齢者でも
極めて容易に保護層を粘着剤層から剥離することができ
る利便性に優れた温熱貼付剤に関するものである。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a hot patch such as a disposable body warmer, a hot shipping agent, a hot plaster and the like for medical or medical use, home use, and leisure use. More specifically, there is provided a reinforcing portion formed on a side or a corner of the protective layer adhered over substantially the entire surface of the heat generating component agent or over the entire surface of the pressure-sensitive adhesive layer partially or in a frame shape or the like. Also, the present invention relates to a highly convenient heat-resistant patch which enables even an elderly person to peel off the protective layer from the pressure-sensitive adhesive layer very easily just by flipping the formation portion of the reinforcing portion with a fingertip.
【0002】[0002]
【従来の技術】近年、高齢化社会が進み腰痛、ひじ痛、
ひざ痛、肩痛等の症状を訴える人が増加する傾向にあ
る。そのため対症療法による温熱貼付剤が多く利用され
ている。温熱貼付剤としては、温熱シップ剤,温熱プラ
スター,使い捨てカイロ等の発熱部材上に、粘着剤層が
展着され、その粘着剤層を保護するためポリエチレン又
はポリプロピレン等の保護層が用いられている。以下に
従来の温熱貼付剤について説明する。図5(a)は従来
の温熱貼付剤の斜視図であり、図5(b)はそのA−A
線断面図である。10は従来の温熱貼付剤、11は温熱
シップ剤,温熱プラスター,使い捨てカイロ等よりなる
発熱部材、11aは鉄粉,還元鉄粉,活性炭,アルミ
ナ,シリカゲル,木炭,吸水性高分子,塩化ナトリウ
ム,塩化カリウム,塩化マグネシウム,塩化鉄,酢酸,
クロル酢酸,水,アクリル系吸水高分子等の発熱原料を
適宜配合処方した化学発熱剤、11bは化学発熱剤11
aを収容する偏平状袋体、11cは偏平状袋体11bを
構成する合成樹脂や合成繊維,天然繊維等からなる通気
性基材フィルム、11dは通気性フィルム11cを補強
する補強用フィルム、12は接着層、13は接着層12
を介して偏平状袋体11bの一面に接着された支持体1
3aと支持体13a上に展着された粘着剤13bとを備
えた粘着剤層、14は粘着剤層13の表面全面に密着し
て貼着された極めて薄い柔軟性を有するフィルムやシー
ト,金属箔等からなる保護層である。以上のように構成
された温熱貼付剤について、以下その使用方法を説明す
る。まず温熱貼付剤10の隅部を何度も爪で探って粘着
剤層13と保護層14とが剥がれやすいようにした後、
保護層14を爪で剥ぎ、次いで、発熱部材11がよじれ
て粘着剤層同士が絡みつかないように注意しながら保護
層14を剥離した後、発熱部材11を持って患部に貼付
したり、またはシャツ等の下着の表面に貼付して利用さ
れていた。2. Description of the Related Art In recent years, an aging society has progressed, and low back pain, elbow pain,
There is a tendency for more people to complain of symptoms such as knee pain and shoulder pain. Therefore, hot patches by symptomatic treatment are often used. As the hot patch, a pressure-sensitive adhesive layer is spread on a heating member such as a heat-shipping agent, a heat plaster, a disposable body warmer, and a protective layer such as polyethylene or polypropylene is used to protect the pressure-sensitive adhesive layer. . Hereinafter, a conventional hot patch will be described. FIG. 5A is a perspective view of a conventional hot patch, and FIG.
It is a line sectional view. Reference numeral 10 denotes a conventional hot patch, 11 denotes a heating member made of a heat-shipping agent, a heat plaster, a disposable body warmer, etc., 11a denotes iron powder, reduced iron powder, activated carbon, alumina, silica gel, charcoal, water-absorbing polymer, sodium chloride, Potassium chloride, magnesium chloride, iron chloride, acetic acid,
A chemical exothermic agent prepared by appropriately mixing and formulating exothermic materials such as chloroacetic acid, water and an acrylic water-absorbing polymer.
a, a permeable bag film made of a synthetic resin, synthetic fiber, natural fiber, or the like constituting the flat bag member 11b; 11d, a reinforcing film for reinforcing the permeable film 11c; Is the adhesive layer, 13 is the adhesive layer 12
1 adhered to one surface of the flat bag 11b through
A pressure-sensitive adhesive layer comprising a pressure-sensitive adhesive 3a and a pressure-sensitive adhesive 13b spread on a support 13a; a thin film or sheet 14 having an extremely thin flexibility adhered in close contact with the entire surface of the pressure-sensitive adhesive layer 13; It is a protective layer made of foil or the like. The method of using the hot patch constructed as described above will be described below. First, the adhesive layer 13 and the protective layer 14 are easily peeled off by repeatedly searching the corners of the hot patch 10 with nails.
After peeling off the protective layer 14 with a nail, and then peeling off the protective layer 14 while paying attention so that the heat-generating member 11 is not kinked and the pressure-sensitive adhesive layers are not entangled, the heat-generating member 11 is attached to an affected part or It was used by attaching it to the surface of underwear such as a shirt.
【0003】[0003]
【発明が解決しようとする課題】しかしながら上記従来
の構成では、温熱貼付剤の多くは白色等からなる一色の
支持体の上面に展着された白色又は白色透明の粘着剤層
が形成され、その表面を極めて薄く柔軟性のある透明色
のフィルムからなる保護層で覆っているため保護層と粘
着剤層の区別がつき難く剥離位置が不明確なため保護層
が摘み難いという問題点を有していた。また、保護層と
発熱部材とが同形で同じ大きさのため指先を保護層の先
端に出しても指先がうまくかからないという問題点を有
していた。更に、粘着剤層は増粘作用を有する増粘剤等
を用いているため粘着性が極めて強く、その粘着性を有
する粘着剤層に薄肉の保護層が密着して貼着されている
ため、患者がいざ患部に貼ろうとしても、保護層が剥ぎ
取り難く保護層を剥ぎ取ることにいたずらに時間を浪費
し、イライラすることも多く、剥離作業が困難で使用上
大変不便という問題点を有していた。特に高齢者にとっ
ては、指先も若いときほど器用ではなくなり、しかも視
力等も低下していることから、薄肉透明の保護層が粘着
剤層等と同色化し密着しているため識別が困難で粘着剤
層から保護層を剥ぎ取ることは大きな負担を強いるとい
う問題点を有していた。また、保護層も発熱部材も共に
柔軟なため発熱部材がよじれて粘着剤層同士が絡み付
き、もとの状態にもどすことに時間を要する等の問題点
を有していた。However, in the above-mentioned conventional construction, most of the hot patches have a white or white transparent pressure-sensitive adhesive layer spread on the upper surface of a one-color support made of white or the like. Since the surface is covered with a protective layer made of a very thin and flexible transparent film, it is difficult to distinguish between the protective layer and the pressure-sensitive adhesive layer. I was Further, since the protective layer and the heat-generating member have the same shape and the same size, there is a problem that the fingertip does not work well even when the fingertip is put on the tip of the protective layer. Furthermore, since the pressure-sensitive adhesive layer uses a thickener and the like having a thickening action, the pressure-sensitive adhesive is extremely strong, and a thin protective layer is closely adhered to the pressure-sensitive adhesive layer having the tackiness, Even if a patient tries to apply it to the affected area, the protective layer is difficult to peel off, and it is time-consuming and often frustrating to peel off the protective layer. Was. Especially for elderly people, the younger their fingertips, the less dexterous they have and the lower their visual acuity, and the like. Stripping the protective layer from the layer had the problem of imposing a heavy burden. In addition, since both the protective layer and the heat generating member are flexible, the heat generating member is twisted and the pressure-sensitive adhesive layers are entangled with each other, so that it takes time to return to the original state.
【0004】本発明は上記従来の問題点を解決するもの
で、粘着剤層に密着されている保護層を高齢者でも手間
をかけずに簡単にかつ容易に、しかも確実に剥離するこ
とができ、使用に当たって粘着剤層同士の絡みつきのな
い構造が簡単でかつ皮膚密着性や薬理効果や薬理持続性
に優れた低原価で量産性に優れた温熱貼付剤を提供する
ことを目的とする。The present invention solves the above-mentioned conventional problems, and enables the elderly to easily and easily peel off the protective layer adhered to the pressure-sensitive adhesive layer without any trouble. It is an object of the present invention to provide a low-cost, mass-productive, heat-resistant patch which has a simple structure in which the pressure-sensitive adhesive layers do not become entangled in use and has excellent skin adhesion, pharmacological effects and pharmacological persistence.
【0005】[0005]
【課題を解決するための手段】この目的を達成するため
に本発明の温熱貼付剤は次のような構成を有している。
請求項1に記載の温熱貼付剤は、発熱部材と、前記発熱
部材の一面に支持体を介して又は介さないでその略全面
又は部分的若しくは枠状に展着された粘着剤層と、前記
粘着剤層の全面に貼着された保護層と、前記保護層の少
なくとも一側部の全面又は部分的若しくはいずれかの側
部の1乃至複数の角部に厚肉状に形成された補強部と、
を備えた構成を有している。請求項2に記載の温熱貼付
剤は、請求項1において、前記補強部がその表面等に文
字,図形,記号等が印刷され、及び/又は着色されてい
る構成を有している。請求項3に記載の温熱貼付剤は、
請求項1乃至2の内いずれか1において、前記補強部が
前記保護層と別個に前記保護層上に接着積層されて形成
されている構成を有している。請求項4に記載の温熱貼
付剤は、請求項1乃至3のうちいずれか1において、前
記保護層及び/又は前記補強部がポリプロピレン,ポリ
エチレン,ポリエステル,ポリ塩化ビニル,ポリスチレ
ン等の合成樹脂のフィルム又はシート、若しくはシリコ
ン加工紙,アルミ箔等から選択されたものである構成を
有している。請求項5に記載の温熱貼付剤は、請求項1
乃至4の内いずれか1において、前記保護層及び/又は
前記補強部の厚みが0.1〜1000μmである構成を
有している。Means for Solving the Problems In order to achieve this object, the hot patch of the present invention has the following constitution.
The heating patch according to claim 1, wherein the heat-generating member, the pressure-sensitive adhesive layer spread on one side of the heat-generating member in a substantially whole or partial or frame-like manner with or without a support. A protective layer adhered to the entire surface of the pressure-sensitive adhesive layer, and a thickened reinforcing portion formed on at least one side of the protective layer, or at least one or a plurality of corners on one or more sides of the protective layer. When,
Is provided. According to a second aspect of the present invention, there is provided the thermal patch according to the first aspect, wherein the reinforcing portion has a structure in which characters, figures, symbols, and the like are printed on its surface or the like and / or are colored. The hot patch according to claim 3,
In any one of claims 1 and 2, the reinforcing portion is formed by being adhered and laminated on the protective layer separately from the protective layer. The thermal patch according to claim 4, wherein the protective layer and / or the reinforcing portion is a film of a synthetic resin such as polypropylene, polyethylene, polyester, polyvinyl chloride, and polystyrene according to any one of claims 1 to 3. Or, it has a configuration selected from a sheet, silicon-processed paper, aluminum foil, or the like. The hot patch according to claim 5 is the same as claim 1.
4 to 4, wherein the protective layer and / or the reinforcing portion has a thickness of 0.1 to 1000 μm.
【0006】ここで、発熱部材としては、種類に制約は
なく、従来公知の発熱を有する部材であればすべて適用
できるものである。例えば、電気利用の発熱部材、乾電
池又は太陽電池等を使用した発熱部材又はペーパー状の
電池、あるいは化学発熱を起こす発熱剤を偏平状袋体に
収容した発熱カイロ等が挙げられる。中でも携帯性や温
湿布効果等の観点から発熱カイロが発熱部材として好適
に用いられる。発熱剤の組成としては鉄粉系、反応助
剤、水及び保水剤から構成されるもので、空気及び水の
共存下で発熱を生起する物質が好んで使用される。具体
的には、鉄粉,還元鉄粉,活性炭,アルミナ,シリカゲ
ル,木炭,吸水性高分子,塩化ナトリウム,塩化カリウ
ム,塩化マグネシウム,塩化鉄,酢酸,クロル酢酸,
水,アクリル系吸水高分子等の発熱原料を適宜配合処方
した組成物である。発熱剤量は0.5〜6g/cm2 ,好
ましくは1〜3g/cm2程度が適当である。発熱剤の種
類にもよるが、発熱剤が1gよりも少なくなるにつれ温
熱効果が得られなくなる傾向があり、また3gを越える
に従い低温火傷の危険性がでてくる傾向がある。又、発
熱剤の温度条件としては粘着剤層の熱安定性を破壊しな
いことがもっとも重要であり、温度設定としては粘着剤
層の表面温度が60℃以下がよく、好ましくは50℃以
下、更に好ましい状態としては45℃以下が最もよく、
特に40℃前後が好ましい。低温火傷を防止し、熱治療
効果を高めるためである。発熱剤組成中にセラミックス
粉を含有させたり、又は発熱部材層と粘着剤層の間にセ
ラミックスの層を設けてもよい。遠赤外線効果により体
内の深部まで温熱効果を付与できる。偏平状袋体は、目
的に応じて2層以上の合成樹脂層で形成されたものでも
よいが、その素材の選択に当たり、ヒートシール性があ
り、簡単に熱融着できるものを選ぶのが好ましい。この
場合、2層以上の合成樹脂層が熱融着できないときに
は、その間にホツトメルト系の接着フィルムを介在させ
てこれらの合成樹脂層を接合してもよいが、このように
構成することにより、片面の通気性フィルムの透湿性が
失われないように注意することを要する。偏平状袋体を
形成する高分子材料としては、例えばポリエチレン,ポ
リプロピレン,ナイロン,ポリエステル,ポリ塩化ビニ
ル,ポリ塩化ビニリデン,ポリウレタン,ポリスチレ
ン,エチレン−酢酸ビニル共重合体ケン化物,エチレン
−酢酸ビニル共重合体,天然ゴム,再生ゴム,合成ゴム
等が挙げられる。偏平状袋体を補強するために織布もし
くは不織布からなる通気性補強用フィルムを用いるのが
好ましいが、かかる通気性補強用フィルムは、例えば、
ナイロン,ビニロン,ポリエステル,レーヨン,アセテ
ート,アクリル,ポリエチレン,ポリプロピレン,ポリ
塩化ビニル等の合成繊維、綿、麻、絹等の天然繊維から
選ばれる1種又は2種以上の素材を用いて形成される。Here, the type of the heat-generating member is not limited, and any known heat-generating member can be used. For example, a heating member using electricity, a heating member using a dry cell or a solar cell or a paper-shaped battery, or a heating bag in which a heating agent causing chemical heating is accommodated in a flat bag body may be used. Above all, a heating body is preferably used as a heating member from the viewpoint of portability, warm compressing effect and the like. The composition of the exothermic agent is composed of an iron powder system, a reaction aid, water and a water retention agent, and a substance that generates heat in the presence of air and water is preferably used. Specifically, iron powder, reduced iron powder, activated carbon, alumina, silica gel, charcoal, water-absorbing polymer, sodium chloride, potassium chloride, magnesium chloride, iron chloride, acetic acid, chloroacetic acid,
It is a composition in which exothermic raw materials such as water and an acrylic water-absorbing polymer are appropriately compounded and formulated. The amount of the exothermic agent is suitably 0.5 to 6 g / cm 2 , preferably about 1 to 3 g / cm 2 . Although it depends on the type of exothermic agent, as the exothermic agent is less than 1 g, there is a tendency that the heating effect cannot be obtained, and as the amount of exothermic agent exceeds 3 g, there is a tendency that there is a risk of low-temperature burn. Further, as the temperature condition of the exothermic agent, it is most important that the thermal stability of the pressure-sensitive adhesive layer is not destroyed. As the temperature setting, the surface temperature of the pressure-sensitive adhesive layer is preferably 60 ° C. or less, more preferably 50 ° C. or less, and furthermore The best condition is 45 ° C or less,
Particularly around 40 ° C. is preferable. This is to prevent low-temperature burns and enhance the heat treatment effect. A ceramic powder may be contained in the composition of the heating agent, or a ceramic layer may be provided between the heating member layer and the pressure-sensitive adhesive layer. The far-infrared effect can provide a thermal effect to deep inside the body. The flat bag may be formed of two or more synthetic resin layers depending on the purpose. However, in selecting the material, it is preferable to select a material that has heat sealing properties and can be easily heat-sealed. . In this case, when two or more synthetic resin layers cannot be heat-sealed, these synthetic resin layers may be joined with a hot-melt adhesive film interposed therebetween. Care must be taken not to lose the moisture permeability of the breathable film. Examples of the polymer material forming the flat bag include polyethylene, polypropylene, nylon, polyester, polyvinyl chloride, polyvinylidene chloride, polyurethane, polystyrene, saponified ethylene-vinyl acetate copolymer, and ethylene-vinyl acetate copolymer. Coalesce, natural rubber, recycled rubber, synthetic rubber and the like. It is preferable to use a breathable reinforcing film made of woven or nonwoven fabric to reinforce the flat bag, such a breathable reinforcing film, for example,
Formed using one or more materials selected from synthetic fibers such as nylon, vinylon, polyester, rayon, acetate, acrylic, polyethylene, polypropylene, polyvinyl chloride and the like, and natural fibers such as cotton, hemp and silk. .
【0007】粘着剤層は、各種配合処方によりシャツ等
への衣類への単なる接着剤として、又は水分や湿布液,
湿布用ペースト,薬物を混入して湿布薬として肌を温シ
ップするための層である。粘着剤層は支持体の一面又は
発熱部材が発熱カイロの場合はその一面に略全面にわた
って展着されるか、又は点在状、複数の帯状若しくは波
状に、若しくは1乃至複数の枠状に形成される。基材と
しては、アクリル系共重合体,A−B−A型ブロック共
重合体,脂環族系石油樹脂,軟化剤を有するものが好適
に用いられる。この基材に薬剤を添加することにより外
用の温湿布剤として特に有効に利用される。基材に更に
A−B型ブロック共重合体やその他のポリブテンゴム,
ブチルゴム,シリコーンゴムが用いられる。更に、テル
ペン系樹脂,石油系樹脂などの粘着性付与剤,流動パラ
フィン,オリーブ油,大豆油,牛脂,トン脂等の動植物
油、ポリブテン,低級イソプレン,ワックスなどの接着
力・保持力調整剤、酸化チタン,酸化亜鉛,メタケイ酸
アルミニウム,硫酸カルシウム,リン酸カルシウムなど
の充填剤等を配合してもよい。かくして得られた粘着剤
層は、皮膚への熱伝導が良くなるように水分を含有し、
かつ粘着性の優れたものとするのが望ましい。また発熱
の際に38〜44℃の温度においても軟化し粘着剤層の
膏体が皮膚に残らない適度な凝集性を有することが望ま
しい。例えば、含水するための内容原料としては、CM
C,ポリアクリル酸ナトリウム,カオリン,ゼラチン,
酸化チタン各種架橋剤等を用いることができるが、この
ほかに柔軟性,粘着性等、所望の物性を得るために各種
の原料を用いることができる。尚、吸水性高分子を添加
することにより発汗した汗を吸収し皮膚への密着性を持
続させ、使用感を向上させることができる。また、非転
着性粘着剤を添加することにより転着性を防止できるの
で利便性を向上させ貼付部位を拡大することができる。
A−B−A型ブロック共重合体やA−B型ブロック共重
合体としては、モノビニル置換芳香族化合物Aと共役ジ
オレフィン共重合体Bとのブロック共重合体が好適に用
いられる。具体的にはシェル化学社製のカリフレックス
TR−1101,カリフレックスTR−1107,カリ
フレックスTR−1111等、フィリップペトロリアム
製のソルプレン418やソルプレン311等であり、そ
の配合量は粘着剤組成物中10〜40重量部であり、好
ましくは15〜30重量部である。A−B型ブロック共
重合体を15〜30重量部加えることにより、A−B−
A型ブロック共重合体の薬効成分の相溶性や投錨力、粘
着力を向上させるとともに油状成分による凝集力を改善
することができ、この範囲よりも外れるに従い、これら
の効果を減少させる傾向があるので好ましくない。The pressure-sensitive adhesive layer can be used as a mere adhesive to clothing such as a shirt or the like, depending on various kinds of compounding or prescription.
It is a layer for warming the skin as a poultice by mixing a paste for poultice and a drug. The pressure-sensitive adhesive layer is spread over substantially the entire surface of the support or, when the heating member is a heating body, over the entire surface, or is formed in a dotted shape, a plurality of strips, a wavy shape, or a frame shape. Is done. As the substrate, those having an acrylic copolymer, an ABA type block copolymer, an alicyclic petroleum resin, and a softener are preferably used. By adding a drug to this base material, it can be particularly effectively used as a hot compress for external use. AB-type block copolymer or other polybutene rubber
Butyl rubber and silicone rubber are used. Further, tackifiers such as terpene-based resins and petroleum-based resins, liquid and paraffin, animal and vegetable oils such as olive oil, soybean oil, beef tallow, tongue fat, and adhesive / holding power modifiers such as polybutene, lower isoprene, and wax; Fillers such as titanium, zinc oxide, aluminum metasilicate, calcium sulfate, and calcium phosphate may be added. The pressure-sensitive adhesive layer thus obtained contains water so that heat conduction to the skin is improved,
And it is desirable to have excellent adhesiveness. Further, it is desirable that the adhesive layer has an appropriate cohesive property such that the adhesive layer is softened even at a temperature of 38 to 44 ° C. at the time of heat generation and the plaster of the adhesive layer does not remain on the skin. For example, as a content raw material for containing water, CM
C, sodium polyacrylate, kaolin, gelatin,
Various cross-linking agents such as titanium oxide can be used. In addition, various raw materials can be used to obtain desired physical properties such as flexibility and tackiness. In addition, by adding a water-absorbing polymer, sweat that has been sweated can be absorbed, the adhesion to the skin can be maintained, and the feeling of use can be improved. In addition, the transferability can be prevented by adding a non-transferable pressure-sensitive adhesive, so that the convenience can be improved and the application site can be enlarged.
As the ABA type block copolymer and the AB type block copolymer, a block copolymer of a monovinyl-substituted aromatic compound A and a conjugated diolefin copolymer B is suitably used. Specific examples thereof include Califlex TR-1101, Califlex TR-1107, and Califlex TR-1111 manufactured by Shell Chemical Company, and Solprene 418 and Sorprene 311 manufactured by Philippe Petroleum. It is 10 to 40 parts by weight, preferably 15 to 30 parts by weight. By adding 15 to 30 parts by weight of the AB type block copolymer, AB-
It is possible to improve the compatibility, anchoring power, and adhesive strength of the active ingredient of the A-type block copolymer, and to improve the cohesive strength due to the oily component. As the amount falls outside this range, these effects tend to be reduced. It is not preferable.
【0008】水分としては、単なる水、温泉水、塩化ナ
トリウム水、グリセリン、ハッカ油、サリチル酸メチ
ル、サリチル酸グリコール等常用のものが単独又は複数
配合して用いられるほか、液状のアルコール類、液状の
脂肪酸エステル類等も用いられるが、これらの液体には
メントール、カンフル、非ステロイド剤等常用のものの
他、各種の質を溶解し、更に、分散安定剤として界面活
性剤等を配合したものが用いられる。[0008] As the water, water, hot water, sodium chloride water, glycerin, peppermint oil, methyl salicylate, glycol salicylate and the like, which are used alone or in combination, may be used alone or in combination with liquid alcohols and liquid fatty acids. Esters and the like are also used, but in these liquids, in addition to conventional ones such as menthol, camphor, and non-steroidal agents, various liquids are dissolved, and further, a surfactant or the like as a dispersion stabilizer is used. .
【0009】脂環族系石油樹脂としては、環状骨格を持
った石油系樹脂であり、具体的にはアルコンP−85、
アルコンP−100、アルコンP−125(荒川化学
製)、クイントン(日本ゼオン製)、エスコレッツ30
00(エクソン製)等があり、その配合量は10〜50
重量部であり、好ましくは25〜45重量部である。基
材の柔軟性を調整するためである。The alicyclic petroleum resin is a petroleum resin having a cyclic skeleton, specifically, Alcon P-85,
Alcon P-100, Alcon P-125 (Arakawa Chemical), Quinton (Zeon Corporation), Escolets 30
00 (manufactured by Exxon), etc., and its compounding amount is 10 to 50.
Parts by weight, preferably 25 to 45 parts by weight. This is for adjusting the flexibility of the base material.
【0010】軟化剤としては、高級脂肪酸,液化ゴム,
鉱油等が用いられ、その配合量としては、10〜50重
量部、好ましくは25〜45重量部である。軟化剤を2
5〜45重量部加えることにより、発熱剤の発熱温度に
もよるが、基剤の軟化やダレ,流れを防止するととも
に、柔軟性を調整することができる。この範囲から外れ
るにつれ、これらの効果が得られなくなる傾向が認めら
れる。吸水性高分子としては、自重の10倍以上の水を
吸収しゲル化膨潤するものであり、例えば水溶性ポリマ
ーに軽度な架橋結合を導入した吸水性高分子が、適宜単
独もしくは2種以上の混合でもって処方される。具体的
には、サンウェットIM−300、サンウェットIM−
300MPS、サンウェットIM−1000、サンウェ
ットIM−1000MPS(三洋化成製)等、アクアキ
ープ4S、アクアキープ4SH(製鉄化学製)等、スミ
カゲルSP−520、スミカゲルN−1040(住友化
学製)等、KIゲル201−K、KIゲル−201K−
F2(クラレ製)等、アラソープ800、アラソープ8
00F(荒川化学製)等であり、中でもサンウェットI
M−300MPS、サンウェットIM−1000MP
S、スミカゲルNP−1020、スミカゲルNP−10
40、KIゲル−201K−F2、アラソープ800F
等は特に好ましい。配合量としては、粘着剤組成物中1
〜10重量部であり、好ましくは2〜8重量部である。
吸水性高分子が2重量部よりも少なくなるにつれ汗の吸
収が不充分となり易く、8重量部を越えるにつれ皮膚の
乾燥現象が生じるので好ましくない。その他、使用目的
に応じて、従来公知の老化防止剤、タルクやタンカル等
の無機充填剤,酸化防止剤等が適宜適量配合される。As the softener, higher fatty acids, liquefied rubber,
Mineral oil or the like is used, and its blending amount is 10 to 50 parts by weight, preferably 25 to 45 parts by weight. 2 softeners
By adding 5 to 45 parts by weight, depending on the heat generation temperature of the heat generating agent, it is possible to prevent softening, sagging and flow of the base and to adjust flexibility. As the value deviates from this range, there is a tendency that these effects cannot be obtained. The water-absorbing polymer is one that absorbs water 10 times or more its own weight and gels and swells. For example, a water-absorbing polymer in which a lightly crosslinked bond is introduced into a water-soluble polymer may be used alone or in combination of two or more. Formulated with a mixture. Specifically, Sunwet IM-300, Sunwet IM-
300MPS, Sunwet IM-1000, Sunwet IM-1000MPS (manufactured by Sanyo Chemical), Aquakeep 4S, Aquakeep 4SH (manufactured by Iron & Steel Chemicals), Sumikagel SP-520, Sumikagel N-1040 (manufactured by Sumitomo Chemical), etc. KI gel 201-K, KI gel-201K-
F2 (Kuraray), etc., Arasorp 800, Arasorp 8
00F (manufactured by Arakawa Chemical), etc.
M-300MPS, Sun wet IM-1000MP
S, Sumikagel NP-1020, Sumikagel NP-10
40, KI gel-201K-F2, Arasorp 800F
Etc. are particularly preferred. The mixing amount is 1 in the pressure-sensitive adhesive composition.
10 to 10 parts by weight, preferably 2 to 8 parts by weight.
If the amount of the water-absorbing polymer is less than 2 parts by weight, the absorption of sweat tends to be insufficient, and if it exceeds 8 parts by weight, the skin is dried, which is not preferable. In addition, conventionally known antioxidants, inorganic fillers such as talc and tanker, antioxidants, and the like are appropriately compounded according to the purpose of use.
【0011】薬物としては、経皮吸収可能な薬物を含有
させ、温熱医療用貼付剤として用いることができる。例
えば、皮膚刺激剤及び鎮痛消炎剤としては、サリチル
酸,サリチル酸メチル,サリチル酸グリコール,l−メ
ントール,カンフル,ハッカ油,チモール,ニコチン酸
ベンジルエステル,トウガラシエキス,カプサイシン,
ノニル酸ワニアルアミド,フルピナク,フルフェナム酸
プチル,ピロキシカム,インドメタシン,ケトプロフェ
ン,プラノプロフェン,フェプラゾン,ロキソプロフェ
ン,アンフェナクナトリウム,オキサプロジン,エモル
ファゾン,フェンチアザック,ジクロフェナクナトリウ
ム,ジフルニサール,イブプロフェンピコノール,ベン
ダザック,及びスプロフェン,フェルビナク,テニダッ
プ,ケトロラク,並びにこれらのエステル誘導体、ある
いは塩酸プブレノルフィン,ペンタゾシン,酒石酸プト
ルファノール等が用いられる。中枢神経作用剤(睡眠鎮
静剤、抗てんかん剤、精神神経用剤)としては、フルフ
ェナジン,チオリダジン,ジアゼパム,クロルプロマジ
ン,ニトラゼパム,エスタゾラム,トリアゾラム,ニメ
タゼパム,フルニトラゼパム,ハロセキサゾラム,フル
ラゼパム,クロナゼパム,プロペリシアジン,プロクロ
ルペラジン,アルプラゾラム,オキサゼパム,オキサゾ
ラム,クロキサゾラム,プラゼパム,フルタゾラム,メ
キサゾラム,ロラゼパム,フルジアゼパム,プロマゼパ
ム,メタゼパム,ニコチン等が用いられる。利尿剤とし
ては、ハイドロサイアザイド,ペンドロフルナサイアザ
イド,エチアジド,シクロペンチアジド,ヒドロクロロ
チアジド,ペンフルチド,メチクロチアジド、フロセミ
ド、メトラゾン、ポリチアジド、ベンドロフルメチアジ
ド等が用いられる。血圧降下剤としては、クロニジン,
アルサーオキシロン,レシナミン,メシル酸ジヒドロエ
ルゴトキシン,レセルピン,プラゾシン,カプトプリ
ル,ピンドロール,マレイン酸エナラプリル等が用いら
れる。冠血管拡張剤としては、ニトログリセリン,ニト
ログリコール,ジピリダモール,エフロキサート,トリ
メタジン,ニコランジル,シンナリジン,ナイリドン,
モルシドミニフェジピン等が用いられる。鎮咳去痰剤
(気管支拡張剤,抗アレルギー剤を含む)としては、リ
ン酸コディン,リン酸ジヒドロコディン,塩酸エフェド
リン,塩酸クロルプレナリン,臭化水素酸フェノテロー
ル,硫酸サルプタモール,リン酸ジメモルファン,塩酸
アゼラスチン,塩酸クレンプテロール,塩酸ツロプテロ
ール,塩酸トリメトキノール,塩酸プロカテロール,塩
酸プロムヘキシン,トラニラスト,ヒベンズ酸チベピジ
ン,フマル酸ケトチフェン,フマル酸フォルモテロー
ル,リン酸ベンスプロペリン,グリチルレチン酸等が用
いられる。抗ヒスタミン剤としては、塩酸ジフェンヒド
ラミン,塩酸トリプロリジン,塩酸イソチベンジル,塩
酸プロメタジン,マレイン酸クロルフェニラミン,塩酸
シプロヘプタジン,フマル酸クレマスチン,マレイン酸
カルビノキサミン,マレイン酸ジメチンデン等が用いら
れる。不整脈用剤としては、アルプレノロール,オクス
プレノロール,プクモロール,ブプラノロール,ピンド
ロール,インデノロール,カルテオロール,ブフェトロ
ール,プロプラノロール,チモロール等が用いられる。
強心剤としては、ジキタリス,ユビデカレノン,ジゴキ
シン,メチルジゴキシン,デストラノシド等が用いられ
る。性ホルモンとしては、エストラジオールエナンテー
ト,エストラジオールシピネート,レボノルゲストレ
ル,エストラジオール等が用いられる。副腎皮膚ホルモ
ン剤としては、酢酸ヒドロコルチゾン,ヒドロコルチゾ
ン,プレドニゾロン,トリアムシノロンアセトニド,デ
キサメタゾンリン酸エステル,メチルプレドニゾロン,
酢酸ダイクロリンアセトニド,酢酸デキサメタゾン,デ
キサメタゾン,フルオロメトロン,リン酸ベタメタゾン
ナトリウム,ベタメタゾン,吉草酸ベタメタゾン,プロ
ピオン酸ベクロメタゾン,フルドロキシコルチド,酢酸
ヒドロコルチゾン,ジプロピオン酸ベタメタゾン,フル
オキシノニド,プロピオン酸クロベタゾール,吉草酸ジ
フルコルトロン,ハルシノニド,アムシノニド,吉草酸
プレドニゾロン等が用いられる。局所麻酔剤としては、
リドカイン,アミノ安息香酸エチル,塩酸プロカイン,
ジプカイン,プロカイン等が用いられる。これら薬効成
分は、一種又は必要に応じて二種以上配合されて用いら
れる。配合量としては、薬効を期待できる量が好まし
く、粘着剤全体を100重量部とした場合、0.001
〜20重量部の範囲内で適宜処方される。又、温布薬と
して使用可能な漢方薬のエキス,粉体等も当然使用でき
るものである。[0011] The drug contains a transdermally absorbable drug, and can be used as a patch for hot medical treatment. For example, skin irritants and analgesic anti-inflammatory agents include salicylic acid, methyl salicylate, glycol salicylate, l-menthol, camphor, peppermint oil, thymol, benzyl nicotinate, capsicum extract, capsaicin,
Nonanilic acid wanialamide, flupinac, flufenamic acid butyl, piroxicam, indomethacin, ketoprofen, pranoprofen, feprazone, loxoprofen, ampfenac sodium, oxaprozin, emorfazone, fentiazac, diclofenac sodium, diflunisal, ibuprofenpiconol, prondaxen and sudazafen , Felbinac, tenidap, ketorolac, and their ester derivatives, or pubrenorphine hydrochloride, pentazocine, putorphanol tartrate and the like are used. As central nervous system drugs (sleep sedatives, antiepileptics, psychiatric agents), fluphenazine, thioridazine, diazepam, chlorpromazine, nitrazepam, estazolam, triazolam, nimetazepam, flunitrazepam, halosexazolam, flurazepam, clonazepam, propericidin Prochlorperazine, alprazolam, oxazepam, oxazolam, cloxazolam, prazepam, flutazolam, mexazolam, lorazepam, fludiazepam, promazepam, metazepam, nicotine and the like are used. Examples of diuretics include hydrothiazide, pendroflunathiazide, ethiazide, cyclopenthiazide, hydrochlorothiazide, penflutide, meticlothiazide, furosemide, metrazone, polythiazide, bendroflumethiazide, and the like. Clonidine,
Arthuroxylone, resinamine, dihydroergotoxin mesylate, reserpine, prazosin, captopril, pindolol, enalapril maleate and the like are used. Examples of coronary vasodilators include nitroglycerin, nitroglycol, dipyridamole, efloxate, trimetazine, nicorandil, cinnarizine, nylidone,
For example, molsidominiphedipine is used. Antitussive expectorants (including bronchodilators and antiallergic agents) include codine phosphate, dihydrocodine phosphate, ephedrine hydrochloride, chlorprenaline hydrochloride, fenoterol hydrobromide, salptamol sulfate, dimemorphan phosphate, azelastine hydrochloride Clenpterol hydrochloride, tulopterol hydrochloride, trimethoquinol hydrochloride, procaterol hydrochloride, promhexine hydrochloride, tranilast, tibepidine hibenzate, ketotifen fumarate, formoterol fumarate, bensproperin phosphate, glycyrrhetinic acid, and the like. Examples of the antihistamine include diphenhydramine hydrochloride, triprolidine hydrochloride, isothibenzyl hydrochloride, promethazine hydrochloride, chlorpheniramine maleate, cyproheptadine hydrochloride, clemastine fumarate, carbinoxamine maleate, dimethindene maleate and the like. As the agent for arrhythmia, alprenolol, oxprenolol, pucmorol, bupranolol, pindolol, indenolol, carteolol, bufetrol, propranolol, timolol and the like are used.
As a cardiotonic agent, dikitalis, ubidecarenone, digoxin, methyldigoxin, destranoside and the like are used. As the sex hormone, estradiol enanthate, estradiol cipinate, levonorgestrel, estradiol and the like are used. Adrenal cutaneous hormones include hydrocortisone acetate, hydrocortisone, prednisolone, triamcinolone acetonide, dexamethasone phosphate, methylprednisolone,
Dichlorin acetonide acetate, dexamethasone acetate, dexamethasone, fluorometholone, betamethasone sodium phosphate, betamethasone, betamethasone valerate, beclomethasone propionate, fludoxycortide, hydrocortisone acetate, betamethasone dipropionate, fluoxynonide, clobetasol propionate, valerate Diflucortron, halcinonide, amcinonide, prednisolone valerate and the like are used. As a local anesthetic,
Lidocaine, ethyl aminobenzoate, procaine hydrochloride,
Zipcaine, procaine and the like are used. These medicinal ingredients are used alone or in combination of two or more as necessary. The compounding amount is preferably an amount in which a medicinal effect can be expected.
It is appropriately formulated within the range of 20 to 20 parts by weight. Naturally, extracts and powders of Chinese herbs which can be used as warm cloth medicines can also be used.
【0012】非転着性粘着剤としてはゴム系,アクリル
系,酢酸ビニル系などの有機溶剤型、もしくは水性型な
どの粘着剤を用い、これに反応性官能基を導入して内部
凝集力を高めたものであり、例えばアクリル系モノマー
に対し官能性モノマーを1〜10重量%混入したものが
用いられる。官能性モノマーとしては、次の一般式Iに
よるものを1〜4重量%添加されたものが好ましい。As a non-transferable pressure-sensitive adhesive, a pressure-sensitive adhesive of an organic solvent type such as a rubber type, an acrylic type or a vinyl acetate type, or an aqueous type is used. For example, a mixture of an acrylic monomer and a functional monomer in an amount of 1 to 10% by weight is used. As the functional monomer, a monomer obtained by adding 1 to 4% by weight of the following general formula I is preferable.
【化1】 (ただし式中R1 は、炭素数1〜4の低級アルキル基を
示し、R2 は水素原子又はメチロール基を示す。)ある
いは次の一般式IIによるものを6〜10重量%加えたも
のに酸触媒を添加したもの、Embedded image (Wherein, R 1 represents a lower alkyl group having 1 to 4 carbon atoms, and R 2 represents a hydrogen atom or a methylol group) or 6 to 10% by weight of the following general formula II With acid catalyst,
【化2】 (ただし式中R1 は、水素原子又はメチル基を、R2 は
水素原子又は炭素数1〜6のアルキル基又はアリル基
を、R3は炭素数1〜18のアルキル基を示す。)更に
は次の一般式III による官能性モノマー1〜8重量%添
加したものに外掛けで水溶性もしくは分散性エポキシ化
合物1〜5重量%添加したものなどがあり、これらの非
貼着性粘着剤は何れも公知のものである。Embedded image (Wherein R 1 represents a hydrogen atom or a methyl group, R 2 represents a hydrogen atom or an alkyl group or an allyl group having 1 to 6 carbon atoms, and R 3 represents an alkyl group having 1 to 18 carbon atoms). Are non-adhesive pressure-sensitive adhesives to which 1 to 8% by weight of a functional monomer represented by the following general formula III is added and 1 to 5% by weight of a water-soluble or dispersible epoxy compound is externally added. All are known.
【化3】 (ただし式中R1 は水素原子又はメチル基を示す。
R2 ,R3は水素原子又は炭素数1〜4のアルキル基を
示す。)Embedded image (Wherein, R 1 represents a hydrogen atom or a methyl group.
R 2 and R 3 represent a hydrogen atom or an alkyl group having 1 to 4 carbon atoms. )
【0013】保水剤としては、保水性が高く、発熱体組
成物においてそのベトツキを無くするものであれば特に
限定されるものではないが、具体的には、例えばバーミ
キュライト,シリカ粉,木粉,吸水性ポリマー等のうち
少なくとも一種が挙げられる。The water retention agent is not particularly limited as long as it has high water retention and eliminates stickiness in the heating element composition, and specific examples thereof include vermiculite, silica powder, wood powder, and the like. At least one of water-absorbing polymers and the like is included.
【0014】保護層及び補強部はポリプロピレン,ポリ
エチレン,ポリエステル,ポリ塩化ビニル,ポリ塩化ビ
ニリデン,ポリスチレン等の合成樹脂のフィルムやシー
ト,シリコン加工紙,アルミ箔等の無色又は着色したも
のが用いられる。保護層や補強部は別異の色に着色する
か、又はその一面に文字,記号又は符号等を印刷される
のが望ましい。剥離位置を容易に識別し易くするためで
ある。また、補強部の形成位置は保護層の少なくとも一
側部の全面又は側部に点在的に若しくはいずれかの側部
の1乃至複数の角部に形成される。保護層の形状が大き
い場合や薄肉で腰が弱い合成樹脂からなる場合は、両側
部等に形成してもよい。補強部が保護層の一側部の全面
に形成されるときは、保護層の面積の2%〜50%,好
ましくは4%〜40%,より好ましくは6%〜30%の
幅で形成されるのが好ましい。具体的には補強部の大き
さは0.3〜5cm,好ましくは0.5〜4cm,より好ま
しくは1〜3cmの幅で形成される。補強部の材質にもよ
るが、1cm未満になるにつれ保護層の腰の強化力が弱く
なる傾向が認められ、また、3cmを越えるにつれ保護層
の補強部が広すぎ患部に温熱貼付剤を貼付しながら保護
層を剥離する際に剥離し難くなる傾向が認められるので
好ましくない。尚、補強部の形状は帯状以外に保護層等
をめくり易くするものであれば、丸形や楕円,正方形等
の四辺形、三角形,星型,ハート型,人形等のキャラク
ターその他種々の形状に前述の大きさで形成してもよ
い。保護層の剥離をスムーズに行うことができるととも
に、補強部の表面に剥離位置の表示を印刷でき利便性を
向上させることができるためである。保護層や補強部の
厚みは0.1〜1000μm,好ましくは1〜500μ
m,より好ましくは5〜100μmの範囲で形成され
る。保護層の腰を強くし温熱貼付剤の補強部の形成部の
端部を指先でこするだけで支持体のめくれを容易にする
とともに、従来の生産ラインをそのまま使用できるの
で、剥離性ならびに製造工程上の面から好ましい。ま
た、補強部が保護層上に接着積層された補強部からなる
ときは、補強部は保護層と同種又は異種の材料で形成し
接着剤で接着してもよいが、合成樹脂の場合、同種の材
料を用いると熱接着で容易に接着積層できるので好まし
い。補強部は保護層が薄肉で腰が弱い場合、保護層より
厚めに形成するか、保護層より腰の強い合成樹脂で形成
するのが好ましい。保護層が腰の強い合成樹脂で形成さ
れる場合は同じ厚みかそれよりも薄く形成してもよい。
保護層の剥離作業を容易にすることができるためであ
る。As the protective layer and the reinforcing portion, a colorless or colored material such as a synthetic resin film or sheet such as polypropylene, polyethylene, polyester, polyvinyl chloride, polyvinylidene chloride, and polystyrene, siliconized paper, and aluminum foil is used. It is desirable that the protective layer and the reinforcing portion be colored in a different color or that a character, a symbol, a code, or the like be printed on one surface thereof. This is to make it easy to identify the peeling position. The reinforcing portion is formed on at least one side of the protective layer or on one or a plurality of corners of any side of the protective layer. When the shape of the protective layer is large, or when the protective layer is made of a synthetic resin having a small thickness and low rigidity, the protective layer may be formed on both sides. When the reinforcing portion is formed on the entire surface of one side of the protective layer, it is formed with a width of 2% to 50%, preferably 4% to 40%, more preferably 6% to 30% of the area of the protective layer. Preferably. Specifically, the size of the reinforcing portion is 0.3 to 5 cm, preferably 0.5 to 4 cm, and more preferably 1 to 3 cm. Depending on the material of the reinforcing part, there is a tendency that the strength of the protective layer's waist becomes weaker when it is less than 1 cm, and when it exceeds 3 cm, the reinforcing part of the protective layer is too wide and the hot patch is applied to the affected part. While the protective layer is peeled off while peeling, a tendency to be difficult to peel off is recognized, which is not preferable. In addition, the shape of the reinforcing portion is not limited to a band shape, but may be a round shape, an ellipse, a square shape such as a square, a triangle, a star shape, a heart shape, a character such as a doll, or various other shapes as long as it is easy to turn over the protective layer. It may be formed in the aforementioned size. This is because the peeling of the protective layer can be performed smoothly, and the display of the peeling position can be printed on the surface of the reinforcing portion, so that the convenience can be improved. The thickness of the protective layer or the reinforcing portion is 0.1 to 1000 μm, preferably 1 to 500 μm.
m, more preferably in the range of 5 to 100 μm. It is easy to turn up the support simply by rubbing the end of the reinforcing part of the thermal adhesive with the fingertip by strengthening the protective layer, and the conventional production line can be used as it is, so it can be peeled off and manufactured. It is preferable from the viewpoint of the process. When the reinforcing portion is formed of a reinforcing portion bonded and laminated on the protective layer, the reinforcing portion may be formed of the same or different material as the protective layer and adhered with an adhesive. The use of the above material is preferable because it can be easily bonded and laminated by thermal bonding. When the protective layer is thin and stiff, the reinforcing portion is preferably formed to be thicker than the protective layer or to be formed of a synthetic resin stiffer than the protective layer. When the protective layer is formed of a stiff synthetic resin, the protective layer may have the same thickness or a smaller thickness.
This is because the work of peeling the protective layer can be facilitated.
【0015】[0015]
【作用】この構成により、保護層の端部に腰の強い柔軟
な補強部が形成されているので、補強部で補強された部
分の温熱貼付剤の端部を指先でこするだけで保護層や支
持体を容易にめくることができる。また、補強部により
補強された保護層の末端部に指先を触れるだけでその部
分の粘着剤層との剥離を容易に行うことができるので、
温熱貼付剤の一部を摘み、更に保護層の補強された末端
部を摘み取り開くだけで、極めて容易に粘着剤層より保
護層を剥離することができる。また、保護層の側部に帯
状に形成された補強部は保護層のたるみを防止すること
ができるので、保護層に追隋性の良い粘着剤層のたるみ
を防止し粘着剤層同士が絡み付くことなく、しかもしわ
を寄せることなく剥離することができる。補強部を保護
層と別に補強部で接着積層して形成することにより、既
存の生産ラインを活用できる。このようにして得られた
温熱貼付剤は、肩こり、腰痛、打ち身、捻挫等の疾患に
使用され、温熱による治療効果を充分期待できるもので
あり、又、使用上特に問題を生じていた気触れの発生
を、本発明の温熱貼付剤に吸汗性を持たせることにより
著しく抑制する。薬効成分を配合した粘着剤層を付与し
たので温熱貼付剤は特に長時間貼付しても気触れの原因
と考えられる汗を充分に吸収するため、その発生を著し
く抑制するものである。又、温熱効果もあり、人体皮膚
に対する薬物の経皮吸収が一段と向上し、薬効発現性が
速く治療効果においても好ましいものである。偏平状袋
体に発熱剤を収容した化学発熱型の発熱カイロ型のもの
が携帯性に優れている。発熱体組成物を封入してなる偏
平状袋体からなる発熱部材の他面側、つまり通気性フィ
ルム側と反対側層(バックグランド)に湿布層を設ける
ことにより温熱湿布剤としても使用できる。According to this structure, since a flexible and stiff reinforcing portion is formed at the end of the protective layer, the protective layer can be rubbed with the fingertip only at the end of the hot patch at the portion reinforced by the reinforcing portion. And the support can be easily turned. In addition, since the end of the protective layer reinforced by the reinforcing portion can be easily separated from the pressure-sensitive adhesive layer only by touching a fingertip thereof,
The protective layer can be peeled off from the adhesive layer very easily only by pinching a part of the hot patch and further pinching and opening the reinforced end of the protective layer. In addition, the reinforcing portion formed in a strip shape on the side of the protective layer can prevent the protective layer from sagging, so that the adhesive layer with good adherence to the protective layer can be prevented and the adhesive layers are entangled with each other. It can be peeled off without wrinkling. The existing production line can be used by forming the reinforcing portion by bonding and laminating the reinforcing portion separately from the protective layer. The hot patch obtained in this manner is used for diseases such as stiff shoulders, back pain, bruising, sprains, etc., and can be expected to have a sufficient therapeutic effect by heat. Is significantly suppressed by imparting sweat absorbency to the hot patch of the present invention. Since a pressure-sensitive adhesive layer containing a medicinal component is provided, the heat-sensitive patch sufficiently absorbs sweat, which is considered to be a cause of touch even when applied for a long period of time, and thus significantly suppresses the generation thereof. It also has a warming effect, further enhances percutaneous absorption of the drug to the human body skin, has a rapid onset of drug effect, and is preferable in terms of therapeutic effect. A heat-generating heating type of a chemical heating type in which a heating agent is contained in a flat bag is excellent in portability. By providing a poultice layer on the other side of the heat generating member made of a flat bag enclosing the heat generating composition, that is, on the side opposite to the air permeable film side (background), it can be used as a hot compress.
【0016】[0016]
【実施例】以下本発明の一実施例について、図面を参照
しながら説明する。 (実施例1)図1は本発明の第1実施例の温熱貼付剤の
斜視図である。1は第1実施例の温熱貼付剤、2は化学
発熱剤を内包した偏平状袋体からなる発熱部材、3は発
熱部材2の一面の全面に接着もしくは一体に積層された
支持体、4は支持体3の一面の全面に展着されたスチレ
ン−イソプレン−スチレンブロック共重合体,アルコン
P−85(脂環族系石油樹脂),軟化剤としての鉱油流
動パラフィン,吸水性高分子としてアクリル系吸水性樹
脂を含有した粘着剤層、5は粘着剤層4の全面に貼着さ
れた保護層、6は粘着剤層4の一側部の全面に貼着され
た補強部、7は補強部6の表面に剥離位置等を印刷で解
り易く表示した表示部、8は保護層5の端部である。粘
着剤層4は、次の処方で調整した。スチレン−イソプレ
ン−スチレンテレブロック共重合体100部、スチレン
−イソプレン共重合体10部、流動パラフィン150
部、ロジン変性マレイン酸樹脂50部を窒素ガス気流中
で140〜150℃に加熱し溶解する。この溶解物(約
150℃)を約120℃まで冷却した後、サリチル酸メ
チル30部、l−メントール21部を添加・混合して均
一なものとした。これを展延機を用いて支持体上に厚さ
約1mmに展延した。An embodiment of the present invention will be described below with reference to the drawings. (Embodiment 1) FIG. 1 is a perspective view of a hot patch of the first embodiment of the present invention. 1 is a heating patch of the first embodiment, 2 is a heating member composed of a flat bag body containing a chemical heating agent, 3 is a support adhered or integrally laminated on the entire surface of one surface of the heating member 2, and 4 is Styrene-isoprene-styrene block copolymer, Alcon P-85 (alicyclic petroleum resin), mineral oil liquid paraffin as a softening agent, acrylic as a water-absorbing polymer A pressure-sensitive adhesive layer containing a water-absorbent resin, 5 is a protective layer attached to the entire surface of the adhesive layer 4, 6 is a reinforcing portion attached to the entire surface of one side of the adhesive layer 4, and 7 is a reinforcing portion. Reference numeral 8 denotes an end portion of the protective layer 5 on the surface of which the peeling position and the like are clearly displayed by printing. The pressure-sensitive adhesive layer 4 was prepared according to the following formulation. 100 parts of styrene-isoprene-styrene tereblock copolymer, 10 parts of styrene-isoprene copolymer, liquid paraffin 150
Parts and 50 parts of a rosin-modified maleic resin are heated and dissolved at 140 to 150 ° C. in a nitrogen gas stream. After cooling the melt (about 150 ° C.) to about 120 ° C., 30 parts of methyl salicylate and 21 parts of 1-menthol were added and mixed to obtain a uniform product. This was spread on a support to a thickness of about 1 mm using a spreading machine.
【0017】以上のように構成された本実施例の温熱貼
付剤について、以下その使用方法を説明する。使用者
は、保護層5の端部8が補強部6aにより積層形成され
ているので、保護層5の端部8は腰が強く補強されてい
る。そこで、保護層5の端部8を指先でこすると、保護
層5の端部8をその弾力性でめくることができる。そこ
で、めくれた保護層5もしくは支持体3の端部を指で摘
むと保護層5と粘着剤層4が少し剥離する。次いで、露
出した粘着剤層4を患部に当て保護層5を剥離しながら
手を当てて患部に貼付していく。以上のように本実施例
によれば、保護層の側部が補強部で補強され腰が強化さ
れているので、指先でこするだけで容易に保護層と粘着
剤層を剥ぐことができ、更に、少し剥いで露出した粘着
剤層を患部に当てながら発熱部材に手を当てて保護層を
剥離していくだけで、手を汚すことなく更に温熱貼付剤
にシワがよったりすることなくきれいに患部に貼付する
ことができる。尚、本実施例では保護層の一側部に補強
部を接着積層した温熱貼付剤について説明したが、補強
部を保護層の両側部に接着積層して形成してもよい。保
護層が薄肉の合成樹脂製フィルムからなる場合に、温熱
貼付剤のネジレやシワの発生を防ぎながら粘着剤層をス
ムーズに患部に貼付できる。また、補強部を接着積層す
る代わりに保護層と一体に補強部を押出成形しても同様
の効果を得ることができるとともに、補強部を用いる生
産方式に比べ生産工数の削減化が可能で生産性を上げる
ことができる。The method of using the hot patch of the present embodiment thus constituted will be described below. Since the end 8 of the protective layer 5 is laminated by the reinforcing portion 6a, the user has a strong reinforcement at the end 8 of the protective layer 5. Therefore, when the end 8 of the protective layer 5 is rubbed with a fingertip, the end 8 of the protective layer 5 can be turned with its elasticity. Then, when the edge of the rolled-up protective layer 5 or the support 3 is pinched with a finger, the protective layer 5 and the pressure-sensitive adhesive layer 4 are slightly peeled off. Next, the exposed pressure-sensitive adhesive layer 4 is applied to the affected area, and the protective layer 5 is peeled off and the hand is applied to adhere to the affected area. As described above, according to the present embodiment, since the side portions of the protective layer are reinforced by the reinforcing portions and the waist is reinforced, the protective layer and the adhesive layer can be easily peeled off only by rubbing with a fingertip, In addition, the protective layer is peeled off by simply touching the heat generating member while applying the exposed adhesive layer to the affected area by slightly peeling it off, so that the affected area can be cleanly cleaned without fouling the hands and without wrinkling the hot patch. Can be stuck on. In this embodiment, the description has been given of the thermal adhesive patch in which the reinforcing portion is bonded and laminated on one side of the protective layer. However, the reinforcing portion may be formed by bonding and laminating on both sides of the protective layer. When the protective layer is made of a thin synthetic resin film, the pressure-sensitive adhesive layer can be smoothly adhered to the affected area while preventing twisting and wrinkling of the hot patch. In addition, the same effect can be obtained by extruding the reinforcing portion integrally with the protective layer instead of bonding and laminating the reinforcing portion, and the number of production steps can be reduced as compared with the production method using the reinforcing portion. Can increase the quality.
【0018】(実施例2)図2は本発明の第2実施例の
温熱貼付剤の斜視図である。2は発熱部材、3は支持
体、4は粘着剤層、5は保護層、7は表示部、8は保護
層5の端部であり、これらは第1実施例の温熱貼付剤と
同様なものなので同一の符号を付し説明を省略する。粘
着剤層は実施例1と同様にして調整したものを用いた。
1bは第2実施例の温熱貼付剤、6bは保護層5の一側
部の角部に補強部として接着積層された正方形状の補強
部である。尚、補強部6bは正方形の代わりに両辺を角
部の両辺と合わせた直角三角形や丸形等にしても保護層
5の剥離部の腰を強化することができる。Embodiment 2 FIG. 2 is a perspective view of a hot patch of a second embodiment of the present invention. 2 is a heat generating member, 3 is a support, 4 is an adhesive layer, 5 is a protective layer, 7 is a display portion, 8 is an end of the protective layer 5, and these are the same as those of the hot patch of the first embodiment. Therefore, the same reference numerals are given and the description is omitted. The pressure-sensitive adhesive layer used was prepared in the same manner as in Example 1.
Reference numeral 1b denotes a hot patch of the second embodiment, and reference numeral 6b denotes a square reinforcing portion adhered and laminated as a reinforcing portion on one side corner of the protective layer 5. Note that the reinforcing portion 6b can strengthen the stiffness of the peeled portion of the protective layer 5 by forming a right-angled triangle or a round shape in which both sides are combined with both sides of the corner instead of a square.
【0019】(実験例)次に、実施例1,2の温熱貼付
剤を用い、50代乃至70代の女性パネラー各10人に
ついて、剥離時間及び皮膚密着性,薬理効果持続時間の
確認試験を行った。その結果を(表1)に示した。(Experimental Example) Next, using the thermal patches of Examples 1 and 2, confirmation tests of the peeling time, skin adhesion, and duration of the pharmacological effect were conducted on 10 female panelists in their 50s and 70s. went. The results are shown in (Table 1).
【表1】 表中、剥離時間は各パネラーに5枚づつ本実施例の温熱
貼付剤を渡し、温熱貼付剤の保護層を剥ぎ取るまでの時
間である。皮膚密着性は、自然剥離の有無,剥離時の痛
感や糊残り等で判断し良、普通、不可で評価した。尚、
比較例として、市販されている温熱貼付剤を用いて実施
例1,2と同一の条件で剥離試験を行った。この(表
1)から明らかなように本実施例1,2のものは比較例
に対し、剥離時間は1/4〜1/7の極めて短い時間で
老人でも極めて容易に剥離できることがわかった。ま
た、本実施例の粘着剤処方により比較例に対し、薬理効
果持続時間が1.5倍以上も優れ更に皮膚密着性におい
ても優れ、また、実施例1と2の比較から粘着剤層に幅
広く補強部を形成したほうが剥離し易いことがわかっ
た。[Table 1] In the table, the peeling time is the time required for transferring five sheets of the hot patch of this example to each panelist and stripping the protective layer of the hot patch. The skin adhesion was evaluated as good, normal, or not by judging the presence or absence of spontaneous exfoliation, the pain at the time of exfoliation, and adhesive residue. still,
As a comparative example, a peeling test was performed under the same conditions as in Examples 1 and 2 using a commercially available hot patch. As is clear from Table 1, the peeling time of Examples 1 and 2 is very short, which is 1/4 to 1/7 of that of Comparative Example, so that even an elderly person can peel off very easily. In addition, the pharmacological effect duration was more than 1.5 times as good as that of the comparative example and the skin adhesion was also excellent compared with the comparative example, and the adhesive layer was widely applied to the adhesive layer from the comparison of Examples 1 and 2. It was found that the formation of the reinforcing portion facilitated peeling.
【0020】(実施例3)図3は本発明の第3実施例の
温熱貼付剤の斜視図である。2は発熱部材、3は支持
体、4は粘着剤層、5は保護層、8は保護層5の端部で
あり、これらは第1実施例の温熱貼付剤と同様なものな
ので同一の符号を付し説明を省略する。1cは第3実施
例の温熱貼付剤、6cは部分的に保護層5の両端部に補
強部として接着積層された直角三角形状の補強部であ
る。保護層5の両側部が補強されているのでいずれの側
からでも保護層5を剥離することができる。尚、補強部
6cは保護層5の全ての隅部に形成してもよい。いずれ
の側からも剥離することができ利便性を向上させること
ができる。(Embodiment 3) FIG. 3 is a perspective view of a hot patch according to a third embodiment of the present invention. 2 is a heat generating member, 3 is a support, 4 is an adhesive layer, 5 is a protective layer, 8 is an end of the protective layer 5, and these are the same as those of the hot patch of the first embodiment. And the description is omitted. Reference numeral 1c denotes a hot patch of the third embodiment, and 6c denotes a right-angled triangular reinforcing portion partially adhered and laminated as a reinforcing portion on both ends of the protective layer 5. Since both sides of the protective layer 5 are reinforced, the protective layer 5 can be peeled off from either side. Note that the reinforcing portions 6c may be formed at all corners of the protective layer 5. Peeling can be performed from either side, and convenience can be improved.
【0021】(実施例4)図4は本発明の第4実施例の
温熱貼付剤の斜視図である。2は発熱部材、3は支持
体、4は粘着剤層、5は保護層、7は表示部、8は保護
層5の端部であり、これらは第1実施例の温熱貼付剤と
同様なものなので同一の符号を付し説明を省略する。1
dは第4実施例の温熱貼付剤、6dは保護層5の一側部
の中央部に補強部として部分的に接着積層された補強部
である。中央部に表示層7が形成された補強部6dを有
しているので、剥離位置を容易に視認し剥離することが
できる。(Embodiment 4) FIG. 4 is a perspective view of a hot patch according to a fourth embodiment of the present invention. 2 is a heat generating member, 3 is a support, 4 is an adhesive layer, 5 is a protective layer, 7 is a display portion, 8 is an end of the protective layer 5, and these are the same as those of the hot patch of the first embodiment. Therefore, the same reference numerals are given and the description is omitted. 1
d is the hot patch of the fourth embodiment, and 6d is a reinforcing part partially adhered and laminated as a reinforcing part at the center of one side of the protective layer 5. Since the reinforcing portion 6d in which the display layer 7 is formed is provided at the center, the peeling position can be easily visually recognized and peeled.
【0022】[0022]
【発明の効果】以上のように本発明は、粘着剤層全面に
わたり保護層が貼着され、前記保護層の一側部や角部等
に補強部が形成され、更に前記補強部が着色され、又は
文字等が印刷された構成を有しているので、使用者、特
に高齢者でも極めて容易に剥離部分及びその位置の確認
ができ、その部分の補強部で補強された保護層の末端部
分を指先でこすることにより、保護層の末端部並びに温
熱貼付剤の一部を容易にめくることができるので、その
部分を摘み取り、両者を確実に短時間に分離したのち患
部に直ちに貼付することができる。また補強部に文字,
記号,符号等が印刷されているため剥離位置を容易に確
認することができ、剥離作業に煩わされることがなく、
かつ手を汚すことなく温熱貼付剤を患部に貼付すること
ができ利便性に著しく優れ、更に皮膚密着性や薬効持続
性等に優れた低原価で量産性に適した温熱貼付剤を実現
できるものである。As described above, according to the present invention, a protective layer is adhered to the entire surface of the pressure-sensitive adhesive layer, a reinforcing portion is formed on one side or a corner of the protective layer, and the reinforcing portion is colored. , Or a character or the like is printed, so that even a user, especially an elderly person, can very easily confirm the peeled portion and its position, and the end portion of the protective layer reinforced by the reinforcing portion of the portion. By rubbing with a fingertip, the end part of the protective layer and a part of the hot patch can be easily flipped.Pick the part, separate both parts securely in a short time, and then immediately apply it to the affected part. Can be. In addition, letters on the reinforcement,
Since the symbols, symbols, etc. are printed, the peeling position can be easily confirmed, and the peeling work is not bothersome.
In addition, it is possible to apply a hot patch to the affected area without soiling the hands, and it is extremely convenient and can realize a low-cost, hot patch suitable for mass production with excellent skin adhesion and long-lasting efficacy. It is.
【図1】本発明の一実施例の温熱貼付剤の斜視図FIG. 1 is a perspective view of a hot patch of one embodiment of the present invention.
【図2】本発明の第2実施例の温熱貼付剤の斜視図FIG. 2 is a perspective view of a hot patch of the second embodiment of the present invention.
【図3】本発明の第3実施例の温熱貼付剤の斜視図FIG. 3 is a perspective view of a hot patch of a third embodiment of the present invention.
【図4】本発明の第4実施例の温熱貼付剤の斜視図FIG. 4 is a perspective view of a hot patch according to a fourth embodiment of the present invention.
【図5】(a)従来の温熱貼付剤の斜視図 (b)図5(a)のA−A線断面図5A is a perspective view of a conventional hot patch, and FIG. 5B is a cross-sectional view taken along line AA in FIG.
1,1a,1b,1c,1d 温熱貼付剤 2 発熱部材 3 支持体 4 粘着剤層 5 保護層 6,6a,6b,6c,6d 補強部 7 表示部 8 保護層の端部 10 従来の温熱貼付剤 11 発熱部材 11a 化学発熱剤 11b 偏平状袋体 11c 通気性基材フィルム 11d 補強用フィルム 12 接着層 13 粘着剤層 13a 支持体 13b 粘着剤 14 保護層 1, 1a, 1b, 1c, 1d Thermal adhesive 2 Heating member 3 Support 4 Adhesive layer 5 Protective layer 6, 6a, 6b, 6c, 6d Reinforcing part 7 Display part 8 End of protective layer 10 Conventional thermal adhesive Agent 11 Heating member 11a Chemical heating agent 11b Flat bag 11c Air-permeable base film 11d Reinforcement film 12 Adhesive layer 13 Adhesive layer 13a Support 13b Adhesive 14 Protective layer
───────────────────────────────────────────────────── フロントページの続き (72)発明者 椛島 光政 佐賀県鳥栖市田代大官町408番地 久光 製薬株式会社内 (72)発明者 河田 明 佐賀県鳥栖市田代大官町408番地 久光 製薬株式会社内 (56)参考文献 実開 昭59−169830(JP,U) (58)調査した分野(Int.Cl.7,DB名) A61F 7/02 A61F 7/08 334 ──────────────────────────────────────────────────続 き Continuing on the front page (72) Inventor Mitsumasa Kabashima 408 Address, Tashiro-Daikomachi, Tosu City, Saga Prefecture Hisamitsu Pharmaceutical Co., Ltd. (56) References Japanese Utility Model SHO 59-169830 (JP, U) (58) Fields investigated (Int. Cl. 7 , DB name) A61F 7/02 A61F 7/08 334
Claims (5)
体を介して又は介さないでその略全面又は部分的若しく
は枠状に展着された粘着剤層と、前記粘着剤層の全面に
貼着された保護層と、前記保護層の少なくとも一側部の
全面又は部分的若しくはいずれかの側部の1乃至複数の
角部に厚肉状に形成された補強部と、を備えていること
を特徴とする温熱貼付剤。1. A heat-generating member, a pressure-sensitive adhesive layer which is spread on one surface of the heat-generating member with or without a support, substantially entirely or partially or in a frame shape, and the entire surface of the pressure-sensitive adhesive layer. A protective layer attached to the protective layer, and a reinforcing portion formed in a thick-walled shape on one or more corners on the entire surface of at least one side of the protective layer, partially or on any side thereof. A hot patch, characterized in that:
記号等が印刷され、及び/又は着色されていることを特
徴とする請求項1に記載の温熱貼付剤。2. The method according to claim 1, wherein the reinforcing portion includes a character, a graphic,
The hot patch according to claim 1, wherein a symbol or the like is printed and / or colored.
護層上に接着積層されて形成されていることを特徴とす
る請求項1乃至2の内いずれか1に記載の温熱貼付剤。3. The hot patch as claimed in claim 1, wherein the reinforcing portion is formed by bonding and laminating on the protective layer separately from the protective layer.
プロピレン,ポリエチレン,ポリエステル,ポリ塩化ビ
ニル,ポリスチレン等の合成樹脂のフィルム又はシー
ト、若しくはシリコン加工紙,アルミ箔等から選択され
たものであることを特徴とする請求項1乃至3のうちい
ずれか1に記載の温熱貼付剤。4. The protective layer and / or the reinforcing portion is selected from a film or sheet of a synthetic resin such as polypropylene, polyethylene, polyester, polyvinyl chloride, polystyrene, or the like, or silicon-processed paper, aluminum foil, or the like. The hot patch according to any one of claims 1 to 3, characterized in that:
が0.1〜1000μmであることを特徴とする請求項
1乃至4の内いずれか1に記載の温熱貼付剤。5. The hot patch according to claim 1, wherein the thickness of the protective layer and / or the reinforcing portion is 0.1 to 1000 μm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10200094A JP3188586B2 (en) | 1994-04-16 | 1994-04-16 | Hot patch |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10200094A JP3188586B2 (en) | 1994-04-16 | 1994-04-16 | Hot patch |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH07284506A JPH07284506A (en) | 1995-10-31 |
| JP3188586B2 true JP3188586B2 (en) | 2001-07-16 |
Family
ID=14315543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP10200094A Expired - Lifetime JP3188586B2 (en) | 1994-04-16 | 1994-04-16 | Hot patch |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3188586B2 (en) |
-
1994
- 1994-04-16 JP JP10200094A patent/JP3188586B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JPH07284506A (en) | 1995-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2281366T3 (en) | PREPARATIONS OF ADHESIVES. | |
| CN1235573C (en) | patch | |
| JP4467437B2 (en) | Warm patch | |
| JP4398158B2 (en) | Patch | |
| JP3184534B2 (en) | Medicinal compound comprising N-substituted-o-toluidine derivative and transdermal preparation | |
| JPWO2001095889A1 (en) | Patches | |
| JPWO2001043729A1 (en) | Patches | |
| KR100647480B1 (en) | Patch | |
| JPWO2000048580A1 (en) | Sheet-type patch | |
| JP3466305B2 (en) | Dissolving agent and external preparation containing the dissolving agent | |
| CN101686950B (en) | Catalyst and method for producing poultice | |
| JP3188587B2 (en) | Thermal patch | |
| JPS5936608A (en) | Novel application drug | |
| WO1999036061A1 (en) | Plasticizer and patch containing the plasticizer | |
| CN107205957B (en) | patch | |
| JP3188586B2 (en) | Hot patch | |
| JP4468669B2 (en) | Hypoallergenic patch | |
| JP3525272B2 (en) | Skin sticking sheet | |
| JPH0749042B2 (en) | Thermal patch | |
| JP7349591B1 (en) | Patch with cover material | |
| JP6867210B2 (en) | Patch | |
| JP4700270B2 (en) | Water-containing patch | |
| JPH111428A (en) | Warmth-giving cataplasm sheet | |
| JP2632838B2 (en) | External patch | |
| JPH01297069A (en) | Tacky adhesive agent composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20010410 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090511 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120511 Year of fee payment: 11 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130511 Year of fee payment: 12 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |